Celltrion Presents Remsima SC Clinical Data in Seoul, Reaffirming Product Competitiveness

Celltrion has reinforced the competitive edge and safety profile of its autoimmune disease treatment, Remsima SC, by presenting the latest clinical research data at the 2026 Asia Organization for Crohn's and Colitis (AOCC) and the Korean Association of Intestinal Diseases (IMKASID) international conference in Seoul. This marks the first time these findings have been shared domestically in Korea.

The presented data, derived from a Phase 3 trial conducted in Japan over 44 weeks, reaffirms the drug's therapeutic effectiveness and safety. In Japan, the intravenous formulation of Remsima already commands a substantial 44% market share. Celltrion anticipates significant synergy upon the launch of Remsima SC in Japan, building on the success of its existing product.

“

We have once again solidified the competitiveness and trust in the product by presenting the latest clinical results of Remsima SC.

The study involved 60 Crohn's disease patients in Japan who were switched from the intravenous Remsima to the subcutaneous Remsima SC. Over the 44-week maintenance period, patients consistently maintained clinical remission and endoscopic remission, with no significant safety concerns identified. Celltrion Pharma operated a large booth at the conference to promote the drug and presented findings from real-world data, aiming to boost its prescription in global markets.

“

We will do our best to accelerate prescription expansion by continuously securing clinical evidence in the global market and allowing patients to benefit from the treatment.